Accessibility Menu
 
BioRestorative Therapies logo

BioRestorative Therapies

(NASDAQ) BRTX

Current Price$0.29
Market Cap$6.93M
Since IPO (2009)-100%
5 Year-99%
1 Year-85%
1 Month+19%

BioRestorative Therapies Financials at a Glance

Market Cap

$6.93M

Revenue (TTM)

$359.70K

Net Income (TTM)

$14.24M

EPS (TTM)

$-1.64

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

1.13 (Average)

Price

$0.29

Volume

9,987

Open

$0.27

Previous Close

$0.27

Daily Range

$0.26 - $0.29

52-Week Range

$0.19 - $2.04

BRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioRestorative Therapies

Industry

Biotechnology

Employees

14

CEO

Lance Alstodt

Headquarters

Melville, NY 11747, US

BRTX Financials

Key Financial Metrics (TTM)

Gross Margin

64%

Operating Margin

-44%

Net Income Margin

-40%

Return on Equity

-320%

Return on Capital

-44%

Return on Assets

-3%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

-0.48%

Stock Overview

Market Cap

$6.93M

Shares Outstanding

25.48M

Volume

9.99K

Short Interest

0.00%

Avg. Volume

9.39M

Financials (TTM)

Gross Profit

$335.86K

Operating Income

$15.65M

EBITDA

$15.44M

Operating Cash Flow

$10.79M

Capital Expenditure

$116.07K

Free Cash Flow

$10.91M

Cash & ST Invst.

$2.95M

Total Debt

$0.00

BioRestorative Therapies Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$19.60K

-54.7%

Gross Profit

$34.87K

-187.3%

Gross Margin

-1.78%

N/A

Market Cap

$6.93M

N/A

Market Cap/Employee

$630.24K

N/A

Employees

11

N/A

Net Income

$3.21M

-96.0%

EBITDA

$3.77M

-42.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$2.95M

-72.5%

Accounts Receivable

$15.50K

-91.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-3.49%

N/A

Return on Invested Capital

-43.86%

N/A

Free Cash Flow

$2.45M

-3.9%

Operating Cash Flow

$2.42M

-2.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EVGNEvogene Ltd.
$0.80+3.84%
IMNNImunon, Inc.
$2.94+0.10%
TRAWTraws Pharma, Inc.
$1.70-7.10%
BOLTBolt Biotherapeutics, Inc.
$4.54+12.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
CYCNCyclerion Therapeutics
$6.20+3.00%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.20+0.04%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.43-0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$12.69+0.04%

Questions About BRTX

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.